相关实验视频
Updated: Jul 4, 2025
09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
21.6K
在阿尔茨海默氏病连续体中,状体体积,粉样蛋白负担和认知
Seong Ho Jeong1,2, Chae Jung Park3, Jungho Cha4
1Department of Neurology, Inje University Sanggye Paik Hospital, Seoul, Korea.
Aging and disease
|February 1, 2024
概括
在阿尔茨海默病 (AD) 患者中,状体体积 (CPV) 增加与粉样蛋白-β (Aβ) 负担增加和认知能力下降相关. 这表明CPV是AD进展的潜在生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物标志物 生物标志物
背景情况:
- 胸膜 (CP) 是淋巴系统的组成部分,促进大脑代谢物的清除.
- 了解CP体积 (CPV) 在阿尔茨海默病 (AD) 中的作用对于识别疾病进展标志物至关重要.
研究的目的:
- 为了研究CP体积 (CPV),粉样蛋白-β (Aβ) 负担和AD连续体上个体的认知功能之间的关联.
- 探索CPV作为一种潜在的成像生物标志物,用于AD病理和认知障碍.
主要方法:
- 对AD连续的203名患者和82名健康对照的回顾性分析.
- 大脑磁共振成像 (MRI) 和18F-florbetaben正子发射断层扫描 (PET) 用于评估CPV和Aβ负担.
- 神经心理测试评估了认知功能;多变量线性回归和线性混合模型分析了关系.
主要成果:
- 与对照组相比,在AD组观察到CPV增加 (P < 0.001).
- 较大的CPV与更大的全球Aβ沉积有显著的相关性 (P = 0.002).
- 升高的CPV与较差的一般认知功能,记忆和执行功能 (P < 0.001) 和AD痴呆症患者更快的认知衰退 (P = 0.004) 相关.
结论:
- 状交扩大与大脑中粉样蛋白β沉积的增加有关.
- 增加的CPV与阿尔茨海默病患者的认知障碍有关,特别是在记忆和执行功能方面.
- CPV可以作为阿尔茨海默病进展和认知衰退的有价值的成像生物标志物.
更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.8K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.3K
相关概念视频
01:26Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
01:30Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
01:22Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K